Brief: Alligator Bioscience, Aptevo Therapeutics Announce Positive Interim Data Of Dose Escalation Phase Of ALG.APV-527 Phase 1 Study
07/03/2024 15:34
March 7 (Reuters) -
Alligator Bioscience and Aptevo Therapeutics:
* ALLIGATOR BIOSCIENCE: POSITIVE INTERIM DATA OF DOSE
ESCALATION
PHASE OF ALG.APV-527 PHASE 1 STUDY IN SOLID TUMOR CANCERS
EXPRESSING TUMOR ANTIGEN 5T4
* ALLIGATOR BIOSCIENCE AB: INITIAL INTERIM DATA SHOW
FAVORABLE
DRUG EXPOSURE AND CONFIRM ALG.APV-527 BIOLOGICAL ACTIVITY
Further company coverage: APVO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alligator Bioscience AB
See all newsBrief: Alligator Bioscience Q1 Net Loss SEK 1.4 Million
Sweden's Alligator Bioscience posts Q1 net profit, narrows operating loss
Brief: Alligator Bioscience Q1 EBIT SEK -17.8 Million
Brief: Alligator Bioscience Signs LoI With Unicancer For Phase 3 Mitazalimab Development
Brief: Exercise Of Warrants Brings Alligator Bioscience Net Proceeds Of SEK 12 Mln